Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Treasury Shares (2021 - 2025)

CytomX Therapeutics' Treasury Shares history spans 5 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 57.09% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $2.9 million, up 57.09%, while the annual FY2025 figure was $2.9 million, 57.09% up from the prior year.
  • Treasury Shares reached $2.9 million in Q4 2025 per CTMX's latest filing, up from $998350.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $2.9 million in Q4 2025 to a low of $383750.0 in Q4 2022.
  • Average Treasury Shares over 5 years is $1.4 million, with a median of $1.4 million recorded in 2023.
  • Peak YoY movement for Treasury Shares: skyrocketed 264.96% in 2023, then crashed 67.83% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $868250.0 in 2021, then tumbled by 55.8% to $383750.0 in 2022, then surged by 264.96% to $1.4 million in 2023, then surged by 32.32% to $1.9 million in 2024, then soared by 57.09% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Treasury Shares are $2.9 million (Q4 2025), $998350.0 (Q3 2025), and $585000.0 (Q2 2025).